Eli Lilly (LLY) EBIT Margin (2009 - 2026)

Eli Lilly has reported EBIT Margin for 18 years, with the latest figure at 47.98% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 660.0% year-over-year to 47.98%; the trailing twelve-month figure through Mar 2026 stood at 46.29% (up 787.0% YoY), and the FY2025 full-year result was 44.82%, up 890.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 47.98%, up from 46.15% in the prior quarter.
• The five-year high for EBIT Margin was 47.98% in Q1 2026, with the low at 22.97% in Q1 2023.
• Historically, EBIT Margin has averaged 35.15% across 5 years, with a median of 34.23% in 2024.
• Annual changes were most pronounced in 2023 — EBIT Margin sank 993 bps — and 2025, when it soared 1150 bps.
• Eli Lilly's EBIT Margin stood at 28.44% in 2022, then gained by 13 bps to 32.18% in 2023, then gained by 23 bps to 39.44% in 2024, then climbed by 17 bps to 46.15% in 2025, then rose by 4 bps to 47.98% in 2026.
• The last three EBIT Margin figures came in at 47.98% (Q1 2026), 46.15% (Q4 2025), and 45.57% (Q3 2025), per Business Quant data.